Onconova (ONTX) develops drugs for blood cancer. The company share price has been on the downwards trend since 2014 when it failed a phase 3 clinical trial (called ONTIME) for its lead compound rigosertib. The results for the new phase 3 trials initiated in 2016 (called INSPIRE) are scheduled for the first half of 2020. Using the conditions of the trials, competitive position and also considering the risks, I show how a position in the company's stock makes sense.
Fighting blood cancer
Myelodysplastic syndrome ((MDS)) is one of the most common blood cancers